What is Carmat?
Founded in 2008, Carmat operates at the intersection of medical expertise and precision engineering. The company specializes in the design and manufacturing of innovative artificial heart devices intended to treat patients suffering from severe, end-stage heart failure. As a publicly traded entity since 2019, Carmat has transitioned from a research-heavy startup to a global player in the medical device sector. Its market position is defined by its ability to navigate complex regulatory landscapes while maintaining a focus on high-acuity cardiac care. By addressing one of the leading causes of mortality worldwide, the company maintains a critical role in the evolving landscape of cardiovascular health, leveraging its multi-continental operational footprint to deliver advanced therapeutic solutions.
How much funding has Carmat raised?
Carmat has raised a total of $25.9M across 2 funding rounds:
Other Financing Round
$18.6M
Other Financing Round
$7.4M
Other Financing Round (2022): $18.6M with participation from EIC Accelerator
Other Financing Round (2023): $7.4M led by Sante Technology Holdings
Key Investors in Carmat
Sante Technology Holdings
A diversified holding company with interests in structural building materials and industrial systems, providing strategic capital to support long-term growth initiatives.
EIC Accelerator
A European funding body focused on supporting high-impact, innovative startups and SMEs with the potential to create new markets or disrupt existing ones.
What's next for Carmat?
Looking ahead, the strategic deployment of $7.4M will likely focus on scaling manufacturing capacity and expanding clinical reach across Europe, North America, and Asia. As the company matures, the focus will shift toward long-term patient outcomes and the integration of its artificial heart technology into standard clinical protocols. Investors are closely monitoring the company's ability to sustain its growth trajectory while navigating the rigorous demands of the medical device industry. Future milestones will likely involve further clinical validation and the optimization of supply chain logistics to ensure that these life-saving devices are accessible to a broader patient demographic, thereby solidifying Carmat's leadership in the cardiac innovation space.
See full Carmat company page
